The initial phase of the third phase of Novavax vaccine research has been completed and its effectiveness has reached 89.3%. It so happened that this is good news for one of the Polish biotechnology companies. Mabion has an agreement with Novavaks. The company’s shares are heading towards their all-time high.
- The information about the completion of the initial stage of the third phase of the Novavax vaccine is good news for the Polish company Mabion
- Its shares broke PLN 92 for a while, then fell to just over PLN 85
- It is not certain how much Mabion can actually earn on orders from the Americans and whether they will get permission to sell in the USA. They are to submit the application by September
- More such information can be found on the main page of Onet.pl
The effectiveness of the vaccine marked with the code NVX-CoV2373 was confirmed at the level of 89.3%. Moreover, a significant reduction in the incidence was found for the variant of the virus from South Africa, which may be a sales argument for this specific.
The 60% reduced risk of COVID-19 in vaccinated people in South Africa highlights the value of this vaccine in preventing disease due to a very worrying variant currently circulating in South Africa and spreading worldwide. It is the first COVID-19 vaccine for which we now have objective evidence that it protects against the dominant variant in South Africa
said Professor Shabir Maddi, executive director of the Vaccine and Infectious Disease Analysis (VIDA) Division in Wits, and principal investigator of the Novavax COVID-19 vaccine study in South Africa, said as quoted by Novavax.
Mabion’s success
It so happened that the potential success of the vaccine may also be the success of the Polish company Mabion. Yeah signed a contract with Novavaks in March for the production of a technical batch of active ingredient (antigen to NVX-CoV2373), which is the main component of the vaccine. This is supposed to be the first step towards a potential production deal. The preliminary tests in phase 3 (the end of the third phase of the tests are scheduled for June 2023) have been successfully completed and Mabion will be able to join the Novavax production chain and produce the active ingredient of the vaccine.
How can this benefit a Polish company? There are many unknowns here, so the stock market is working a bit in the dark. On Monday, Mabion’s shares gained less than 4 percent, but for a while exceeded PLN 92, which gave the entire company PLN 1.5 billion. This puts it in the top 60th Warsaw Stock Exchange.
Historically, the highest price of Mabion is PLN 139 from January 2018. In March after publication information about the contract with Novavaks the shares broke PLN 126 for a moment. The quotations ended on Monday at the rate of PLN 85.40. This means that they went up by 139% annually.
The news of the vaccine deal, however, helped sell the company’s new share issue in March, from which it raised PLN 133.7 million gross. This is to significantly improve the long-term financial situation and will allow “significant advancement of strategic plans”. In its history, Mabion showed practically only losses. During the 12 months ending in March 2021, he lost a total of PLN 53 million.
Fourth vaccine in the US?
If Novavax obtains approval from US authorities, it will be a great success for a company that in its 33-year history has not produced any drug that is authorized. By September, he intends to complete the formalities for registration in the US. So far, vaccines of the following companies have been approved there: Pfizer / BioNTech, Moderna and Johnson & Johnson. AstraZeneca has not yet applied for registration there.
Funding – $ 388 million – Novavaks was provided by the Coalition for Epidemic Preparedness Innovations (CEPI). Novavax is working with Indian research institutes to develop vaccines against malaria. In addition to Covid-19, he is also researching vaccines against other viruses: seasonal flu, Ebola and RSV.
–
